Paul Hastings

NetSuite Sendgrid Gmail Mimecast Outlook Google Apps GoDaddy Hosting Greenhouse.io Google Tag Manager Mobile Friendly Apache IoT Micro Remote AI

cell therapy immunooncology autoimmune disease biotechnology: pharmaceutical preparations health care biotechnology research natural killer cells nk cells cancer treatment autoimmune diseases oncology car-nk cells immunotherapy inherent cytotoxicity immune response enhancement allogeneic therapies tumor targeting tumor destruction proprietary technology nk cell expansion therapeutic application next generation therapies toxicity reduction off-the-shelf cell therapy molecular targeting chimeric antigen receptor (car) cd19 targeting nkg2d receptor ox40 costimulation membrane-bound il-15 cryopreservation therapeutic persistence cancer immunotherapy tumor antigen recognition clinical trials safety profile pathogen-fighting immune cells adaptive immune response immune system activation leukemia treatment patient-derived therapies biopharmaceutical innovation therapeutic versatility broad patient applications high-risk patients clinical development cytokine storm prevention solid tumors nkg2d ligands tumor microenvironment t-cell therapy alternative immune cell engineering biotech research marker discovery pharmaceutical applications biopharmaceutical clinical-stage engineered natural killer (nk) cell therapies allogeneic off-the-shelf therapeutic applications nkx101 nkx019 gene-edited therapies car nk cell therapies hematology lupus nephritis patient outcomes innovation healthcare providers research institutions biotechnology therapeutics competitive landscape patient accessibility therapeutic efficacy diverse workforce positive workplace culture health wellness & fitness hospital & health care